New scan could spot hidden prostate cancer spread
NCT ID NCT07615101
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial is testing a new radioactive imaging agent called 68Ga-NYM032, given as an injection before a PET/CT scan, in 365 men newly diagnosed with prostate cancer. The goal is to see if this scan can accurately detect whether the cancer has spread to pelvic lymph nodes, compared to standard tissue analysis after surgery. If it works, it could help doctors decide on the best treatment without needing invasive procedures.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
68Ga-NYM032 (a radioactive imaging agent injected intravenously for PET/CT scans)
What this could lead to
If successful, this could provide a more accurate, non-invasive way to detect whether prostate cancer has spread to nearby lymph nodes, helping guide treatment decisions.
What could go wrong
This is still an experimental imaging agent. It may not prove more accurate than current methods, and results from this single-arm study may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.